184 related articles for article (PubMed ID: 25726031)
1. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
[TBL] [Abstract][Full Text] [Related]
2. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
3. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
4. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
[TBL] [Abstract][Full Text] [Related]
5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
7. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
[TBL] [Abstract][Full Text] [Related]
8. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
9. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
10. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
13. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
14. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
15. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
16. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
[TBL] [Abstract][Full Text] [Related]
18. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
19. Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice.
Kalkan A; Bodegard J; Sundström J; Svennblad B; Östgren CJ; Nilsson PN; Johansson G; Ekman M
Prim Care Diabetes; 2017 Apr; 11(2):184-192. PubMed ID: 27894781
[TBL] [Abstract][Full Text] [Related]
20. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
